Peter Seubert

Summary

Affiliation: Elan Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease
    John P Anderson
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Biol Chem 281:29739-52. 2006
  2. doi request reprint Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse
    Peter Seubert
    Elan Pharmaceuticals, Inc, South San Francisco, Calif 94080, USA
    Neurodegener Dis 5:65-71. 2008
  3. doi request reprint Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific
    Wagner Zago
    Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA 94080, USA
    J Neurosci 32:2696-702. 2012
  4. ncbi request reprint Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease
    Manuel Buttini
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Neurosci 25:9096-101. 2005
  5. doi request reprint Immunotherapy reduces vascular amyloid-beta in PDAPP mice
    Sally Schroeter
    Elan Pharmaceuticals, South San Francisco, California 94080, and Wyeth Pharmaceuticals, Cambridge, Massachusetts 02140, USA
    J Neurosci 28:6787-93. 2008
  6. ncbi request reprint Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
    Wagner Zago
    Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, USA
    Alzheimers Dement 9:S105-15. 2013
  7. pmc Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
    Dora Games
    Neotope Biosciences, South San Francisco, California, USA
    Am J Pathol 182:940-53. 2013
  8. ncbi request reprint Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies
    Michael Lee
    Elan Pharmaceuticals, Inc, So San Francisco, CA 94080, USA
    Ann Neurol 58:430-5. 2005
  9. ncbi request reprint Mice as models: transgenic approaches and Alzheimer's disease
    Dora Games
    Elan Pharmaceuticals, 800 Gateway Blvd, South San Francisco, CA 94080, USA
    J Alzheimers Dis 9:133-49. 2006
  10. doi request reprint Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
    Frederique Bard
    Janssen Alzheimer Immunotherapy Research and Development, LLC, 700 Gateway Blvd, South San Francisco, CA 94080, USA
    Exp Neurol 238:38-43. 2012

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease
    John P Anderson
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Biol Chem 281:29739-52. 2006
    ....
  2. doi request reprint Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse
    Peter Seubert
    Elan Pharmaceuticals, Inc, South San Francisco, Calif 94080, USA
    Neurodegener Dis 5:65-71. 2008
    ....
  3. doi request reprint Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific
    Wagner Zago
    Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA 94080, USA
    J Neurosci 32:2696-702. 2012
    ..These results, taken with prior studies, suggest that N-terminal anti-Aβ antibodies effectively interact with both soluble and insoluble forms of Aβ and therefore appear particularly well suited for testing the Aβ hypothesis of AD...
  4. ncbi request reprint Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease
    Manuel Buttini
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Neurosci 25:9096-101. 2005
    ....
  5. doi request reprint Immunotherapy reduces vascular amyloid-beta in PDAPP mice
    Sally Schroeter
    Elan Pharmaceuticals, South San Francisco, California 94080, and Wyeth Pharmaceuticals, Cambridge, Massachusetts 02140, USA
    J Neurosci 28:6787-93. 2008
    ..These observations raise the possibility that Abeta immunotherapy can potentially slow or halt the course of CAA development in AD that is implicated in vascular dysfunction...
  6. ncbi request reprint Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
    Wagner Zago
    Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, USA
    Alzheimers Dement 9:S105-15. 2013
    ..To better understand the relationship between ARIA and the pathophysiology of AD, we undertook a series of studies in PDAPP mice evaluating vascular alterations in the context of central Aβ pathology and after anti-Aβ immunotherapy...
  7. pmc Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
    Dora Games
    Neotope Biosciences, South San Francisco, California, USA
    Am J Pathol 182:940-53. 2013
    ..These results show that neuritic dystrophy is a prominent pathologic feature of the mThy1-α-syn tg model and suggest that CT α-syn might play an important role in the process of axonal damage in these mice as well as in DLB and PD...
  8. ncbi request reprint Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies
    Michael Lee
    Elan Pharmaceuticals, Inc, So San Francisco, CA 94080, USA
    Ann Neurol 58:430-5. 2005
    ..Furthermore, the antibodies are not capable of binding amyloid precursor protein and would be predicted to be competent in facilitating clearance of amyloid plaques in AD brains...
  9. ncbi request reprint Mice as models: transgenic approaches and Alzheimer's disease
    Dora Games
    Elan Pharmaceuticals, 800 Gateway Blvd, South San Francisco, CA 94080, USA
    J Alzheimers Dis 9:133-49. 2006
    ..As a result, we may see containment or even the elimination of AD in the near future as a direct consequence of these advances...
  10. doi request reprint Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
    Frederique Bard
    Janssen Alzheimer Immunotherapy Research and Development, LLC, 700 Gateway Blvd, South San Francisco, CA 94080, USA
    Exp Neurol 238:38-43. 2012
    ..CNS clearance is markedly slower than in the serum and correlates with binding to deposited amyloid in a transgenic model of Alzheimer's disease...
  11. pmc Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance
    Thierry Bussiere
    Elan Pharmaceuticals, South San Francisco, California, USA
    Am J Pathol 165:987-95. 2004
    ..Our results show that distinct morphological types of plaques are differentially cleared depending upon the isotype of the antibody...
  12. pmc Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease
    Guriqbal S Basi
    Elan Pharmaceuticals, Incorporated, South San Francisco, California 94080, USA
    J Biol Chem 285:3417-27. 2010
    ..These findings provide a structural basis for immunotherapeutic strategies targeting Abeta species postulated to underlie cognitive deficits in AD...
  13. doi request reprint Red blood cells are the major source of alpha-synuclein in blood
    Robin Barbour
    Elan Pharmaceuticals, Inc, South San Francisco, Calif 94080, USA
    Neurodegener Dis 5:55-9. 2008
    ..Alpha-synuclein has been detected in blood, and was found to be elevated in the blood of those individuals with the alpha-synuclein gene multiplication...
  14. ncbi request reprint A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease
    Dale B Schenk
    Elan Pharmaceuticals, San Francisco, CA 94080, USA
    Neurodegener Dis 2:255-60. 2005
    ..These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe...
  15. ncbi request reprint Current progress in beta-amyloid immunotherapy
    Dale Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA
    Curr Opin Immunol 16:599-606. 2004
    ..Abeta immunotherapy is also raising new opportunities and questions about the general role of the immune system in neurodegenerative diseases...
  16. pmc Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity
    Nikolay L Malinin
    Elan Pharmaceuticals, 1000 Gateway Boulevard, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 102:3058-63. 2005
    ..These data suggest that Abeta toxicity is mediated by FISH and ADAM12 and may provide insights into therapeutic strategies for AD treatment...
  17. pmc Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology
    Frederique Bard
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 100:2023-8. 2003
    ..These results indicate that antibody Fc-mediated plaque clearance is a highly efficient and effective process for protection against neuropathology in an animal model of Alzheimer's disease...
  18. pmc The role of animal models in advancing amyloid-beta immunotherapy to the clinic
    Dora Games
    Janssen Alzheimer Immunotherapy Research and Development, LLC, 700 Gateway, Blvd, South San Francisco, CA 94080, USA
    Alzheimers Res Ther 2:22. 2010
    ..While several neuropathologically based results from preclinical studies have translated nicely into AD patients, the full clinical value of Aβ-directed therapies awaits results from trials now in progress...
  19. doi request reprint Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis
    Michael Pride
    Wyeth Research, Collegeville, PA 19426, USA
    Neurodegener Dis 5:194-6. 2008
    ..In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer's disease (AD), approximately 6% of the treated AD patients (18/300) developed meningoencephalitis (ME)...
  20. ncbi request reprint Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid
    Robert G Riekse
    Department of Medicine, Division of Geriatric Medicine, University of Washington School of Medicine, and VA Puget Sound Health Care System, Seattle, WA 98108, USA
    J Alzheimers Dis 10:399-406. 2006
    ..Putative neuroprotective effects of statins may vary in relation to their ability to penetrate into the central nervous system (CNS)...
  21. ncbi request reprint Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
    ..Abeta immunotherapy can clear all Abeta species from the cortex. However, if it is to be used for treatment of established Alzheimer disease, then the residual tau pathology and cerebral amyloid angiopathy require further study...
  22. pmc Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1
    Marion S Buckwalter
    Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA
    J Neurosci 26:11437-41. 2006
    ..Likewise, levels of TGF-beta1 or other immune factors in brains of AD patients may influence the response to Abeta(1-42) immunization...
  23. ncbi request reprint Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease
    Eliezer Masliah
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    Neuron 46:857-68. 2005
    ..These results suggest that vaccination is effective in reducing neuronal accumulation of halpha-syn aggregates and that further development of this approach might have a potential role in the treatment of LBD...
  24. ncbi request reprint Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy
    Brian J Bacskai
    Alzheimer s Disease Research Laboratory, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neurosci 22:7873-8. 2002
    ..Together, these results indicate that clearance of amyloid deposits in vivo may involve, in addition to Fc-dependent clearance, a non-Fc-mediated disruption of plaque structure...
  25. ncbi request reprint Distribution of Abeta peptide in whole blood
    J Randall Slemmon
    Genomics and Biotechnology, Pfizer Global Research and Development, Skokie, IL 60077, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:24-31. 2007
    ..This suggested that there was a pool of Abeta peptide in non-denatured plasma that is occluded from detection by ELISA, perhaps by binding to plasma proteins...